Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2002

01-01-2002 | Conference Report

Factors Associated With Success of the Extreme Drug Resistance Assay in Primary Breast Cancer Specimens

Authors: Robert J. Ellis, Carol J. Fabian, Bruce F. Kimler, Ossama Tawfik, Matthew S. Mayo, Carlos Rubin Decelis, William R. Jewell, Carol Connor, Carol Modrell, Mark Praeger, Marilee McGinness, Rita Mehta, John P. Fruehauf

Published in: Breast Cancer Research and Treatment | Issue 2/2002

Login to get access
Metadata
Title
Factors Associated With Success of the Extreme Drug Resistance Assay in Primary Breast Cancer Specimens
Authors
Robert J. Ellis
Carol J. Fabian
Bruce F. Kimler
Ossama Tawfik
Matthew S. Mayo
Carlos Rubin Decelis
William R. Jewell
Carol Connor
Carol Modrell
Mark Praeger
Marilee McGinness
Rita Mehta
John P. Fruehauf
Publication date
01-01-2002
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2002
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1013843912560

Other articles of this Issue 2/2002

Breast Cancer Research and Treatment 2/2002 Go to the issue

Instructions for Authors

Instructions for Authors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine